9 research outputs found
Supplementary Tables from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
Supplementary Tables S1 through S11</p
Figure S8. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
CB-011 immune-cloaking armoring strategy reduced NK cell proliferation and CAR+ T cell stress signatures.</p
Figure S7. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
CB-011 immune-cloaking armoring strategy suppresses cytotoxic T and NK cellāmediated allograft rejection.</p
Figure S6. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
Antitumor activity of CB-011 CAR-T cells in a xenograft model of multiple myeloma.</p
Figure S3. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
CB-011 cells exhibit in vitro antitumor activity against PBMCs from patients with multiple myeloma.</p
Figure S4. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
Gamma-secretase inhibitor RO4929097 increases BCMA expression on-target cell lines but does not improve CB-011 antitumor efficacy.</p
Figure S5. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
Antitumor activity of CB-011 CAR-T cells in a xenograft model of multiple myeloma.</p
Figure S2. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
In vitro serial rechallenge assay demonstrates long-term cytotoxicity activity of CB-011 against BCMA+ tumor cells.</p
Figure S1. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
chRDNA-mediated gene editing did not result in any off-target editing above the limit of detection.</p